Accordingly, we recently showed in HCC that a combined therapy with a FAK inhibitor plus sorafenib caused a decrease of the global levels of H3K27me3, of the protein levels of HDAC1 and 2, and consequently H3K27ac increased [146]. Here, PTK2 is linked to hepatocellular carcinoma.